Patents by Inventor Clive Svendsen
Clive Svendsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200253684Abstract: The present invention teaches minimally invasive apparatuses and methods for stabilizing and/or guiding medical instruments used in a variety of medical procedures, including (a) introducing one or more substances into a subject's body, (b) removing one or more substances from a subject's body, (c) manipulating a region of a subject's body, or (d) combinations thereof. Among the many advantages of the inventive apparatuses are their simplicity and adaptability to attach to a variety of retractors.Type: ApplicationFiled: November 15, 2019Publication date: August 13, 2020Applicant: Cedars-Sinai Medical CenterInventors: Pablo Avalos, Doniel Drazin, Clive Svendsen
-
Publication number: 20200224140Abstract: Described herein is functionalized glass allowing for robust attachment of extracellular matrix proteins (ECM) withstanding extended culturing periods. By first treating glass with a sulfur silane reagent, the treated glass can be activated via an amine-sulfur linker, after which ECM proteins are attached to the linker. The Inventors observed that this glass treatment combination (sulfur silane-linker-ECM) resisted degradation when compared to conventional surface coatings, such as poly-L-orthinine coated glass.Type: ApplicationFiled: July 13, 2018Publication date: July 16, 2020Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Alexander LAPERLE, Clive SVENDSEN
-
Publication number: 20200157508Abstract: Induced pluripotent stem cell (iPSC)-based organoid technology has tremendous potential to elucidate the intestinal and colonic epithelium's role in health and disease. Described herein are methods and compositions for generation of intestinal and colonic cells from iPSCs. Derivation of iPSCs from subjected afflicted with early onset and very early onset Inflammatory Bowel Disease (IBD), serves as an excellent model for understanding disease pathogenesis.Type: ApplicationFiled: May 18, 2018Publication date: May 21, 2020Applicant: Cedares-Sinai Medical CenterInventors: Robert Barrett, Clive Svendsen, Stephan R. Targan, Michael Workman, Dhruv Sareen
-
Patent number: 10512506Abstract: The present invention teaches minimally invasive apparatuses and methods for stabilizing and/or guiding medical instruments used in a variety of medical procedures, including (a) introducing one or more substances into a subject's body, (b) removing one or more substances from a subject's body, (c) manipulating a region of a subject's body, or (d) combinations thereof. Among the many advantages of the inventive apparatuses are their simplicity and adaptability to attach to a variety of retractors.Type: GrantFiled: April 30, 2014Date of Patent: December 24, 2019Assignee: Cedars-Sinai Medical CenterInventors: Pablo Avalos, Doniel Drazin, Clive Svendsen
-
Publication number: 20190359924Abstract: The invention relates to culturing brain endothelial cells, and optionally astrocytes and neurons in a fluidic device under conditions whereby the cells mimic the structure and function of the blood brain barrier. Culture of such cells in a microfluidic device, whether alone or in combination with other cells, drives maturation and/or differentiation further than existing systems.Type: ApplicationFiled: February 26, 2019Publication date: November 28, 2019Inventors: S. Jordan Kerns, Norman Wen, Carolina Lucchesi, Christopher David Hinojosa, Jacob Fraser, Geraldine Hamilton, Gad Vatine, Samuel Sances, Clive Svendsen, Daniel Levner, Dhruv Sareen
-
Publication number: 20190194606Abstract: Described here are systems and methods for deriving both spinal motor neurons and brain microvascular endothelial cells from induced pluripotent stem cells using distinct methods and combining them in a chip format. Neurons cultured alone in chip microvolume displayed increased calcium transient function and chip-specific gene expression. When seeded with endothelial cells, interaction further enhanced neural function, elicited vascular-neural interaction, niche gene expression with enhanced in vivo-like signatures arising from the chip co-cultures. Development of novel media formulations further allow for improved readout of differentiation process, by eliminating additives that otherwise confound differentiation processes and resulting phenotypes.Type: ApplicationFiled: August 29, 2017Publication date: June 27, 2019Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Gad VATINE, Sam SANCES, Clive SVENDSEN, Dhruv SAREEN, Alexis J. KERL
-
Publication number: 20190194624Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: ApplicationFiled: June 16, 2017Publication date: June 27, 2019Applicant: Cedars-Sinai Medical CenterInventors: Dhruv SAREEN, Loren A. ORNELAS, Clive SVENDSEN
-
Publication number: 20190153395Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.Type: ApplicationFiled: February 1, 2017Publication date: May 23, 2019Applicant: Cedars-Sinai Medical CenterInventors: Robert Barrett, Clive Svendsen, Stephan R. Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani
-
Publication number: 20190136203Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: ApplicationFiled: January 14, 2019Publication date: May 9, 2019Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
-
Patent number: 10221395Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: GrantFiled: June 16, 2016Date of Patent: March 5, 2019Assignee: Cedars-Sinai Medical CenterInventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
-
Publication number: 20190059869Abstract: The present invention teaches apparatuses, systems and methods for performing a variety of medical procedures, including those involving introducing one or more substances into a subjects body.Type: ApplicationFiled: October 28, 2016Publication date: February 28, 2019Applicant: Cedars-Sinai Medical CenterInventors: Pablo Avalos, Doniel Drazin, Clive Svendsen, Michael John Baker, Benjamin Thomas Davies, Mark Sasha Drlik, Julian Snyder Grove, Shelby Suckow
-
Publication number: 20190031992Abstract: Organs-on-chips are microfluidic devices for culturing living cells in micrometer sized chambers in order to model physiological functions of tissues and organs. Engineered patterning and continuous fluid flow in these devices has allowed culturing of intestinal cells bearing physiologically relevant features and sustained exposure to bacteria while maintaining cellular viability, thereby allowing study of inflammatory bowl diseases. However, existing intestinal cells do not possess all physiologically relevant subtypes, do not possess the repertoire of genetic variations, or allow for study of other important cellular actors such as immune cells. Use of iPSC-derived epithelium, including IBD patient-specific cells, allows for superior disease modeling by capturing the multi-faceted nature of the disease.Type: ApplicationFiled: July 31, 2018Publication date: January 31, 2019Inventors: S. Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher David Hinojosa, Jacob Fraser, Jefferson Puerta, Geraldine Hamilton, Robert Barrett, Clive Svendsen, Daniel Levner, Stephen R. Targan, Michael Workman, Dhruv Sareen, Uthra Rajamani, Magdalena Kasendra
-
Publication number: 20190024176Abstract: Modeling Amyotrophic Lateral Sclerosis (ALS) with human induced pluripotent stem cells (iPSCs) aims to reenact embryogenesis, maturation, and aging of spinal motor neurons (spMNs) in vitro. As the maturity of spMNs grown in vitro compared to spMNs in vivo remains largely unaddressed, it is unclear to what extent this in vitro system captures critical aspects of spMN development and molecular signatures associated with ALS. Here, the Inventors compared transcriptomes among iPSC-derived spMNs, fetal, and adult spinal tissues. The Inventors resolved gene networks and pathways associated with spMN maturation and aging. These networks enriched for familial ALS genetic variants and were affected in sporadic ALS. Altogether, the Inventors' findings suggest that developing strategies to further mature and age iPSC-derived spMNs will provide more effective iPSC models of ALS.Type: ApplicationFiled: January 6, 2017Publication date: January 24, 2019Applicant: Cedars-Sinai Medical CenterInventors: Ritchie HO, Clive SVENDSEN
-
Publication number: 20180305651Abstract: The invention relates to culturing brain endothelial cells, and optionally astrocytes and neurons in a fluidic device under conditions whereby the cells mimic the structure and function of the blood brain barrier. Culture of such cells in a microfluidic device, whether alone or in combination with other cells, drives maturation and/or differentiation further than existing systems.Type: ApplicationFiled: October 19, 2016Publication date: October 25, 2018Inventors: S. Jordan Kerns, Norman Wen, Carolina Lucchesi, Christopher David Hinojosa, Jacob Fraser, Geraldine Hamilton, Gad Vatine, Samuel Sances, Clive Svendsen, Daniel Levner, Dhruv Sareen
-
Publication number: 20180298332Abstract: The invention relates to culturing brain endothelial cells, and optionally astrocytes and neurons in a fluidic device under conditions whereby the cells mimic the structure and function of the blood brain barrier. Culture of such cells in a microfluidic device, whether alone or in combination with other cells, drives maturation and/or differentiation further than existing systems.Type: ApplicationFiled: April 17, 2018Publication date: October 18, 2018Inventors: S. Jordan Kerns, Norman Wen, Carolina Lucchesi, Christopher David Hinojosa, Jacob Fraser, Geraldine Hamilton, Gad Vatine, Samuel Sances, Clive Svendsen, Daniel Levner, Dhruv Sareen
-
Publication number: 20180298331Abstract: The invention relates to culturing brain endothelial cells, and optionally astrocytes and neurons in a fluidic device under conditions whereby the cells mimic the structure and function of the blood brain barrier. Culture of such cells in a microfluidic device, whether alone or in combination with other cells, drives maturation and/or differentiation further than existing systems.Type: ApplicationFiled: April 17, 2018Publication date: October 18, 2018Inventors: S. Jordan Kerns, Norman Wen, Carolina Lucchesi, Christopher David Hinojosa, Jacob Fraser, Geraldine Hamilton, Gad Vatine, Samuel Sances, Clive Svendsen, Daniel Levner, Dhruv Sareen
-
Publication number: 20180280611Abstract: The present invention teaches apparatuses, systems and methods for performing a variety of medical procedures, including those involving introducing one or more substances into a subject's body. In some embodiments, the invention teaches automatically performing guided injections into a tissue site (e.g. spinal cord) of a subject by using one or more electronically operated components including a cannula, a syringe pump, and a stereotactic device.Type: ApplicationFiled: October 29, 2015Publication date: October 4, 2018Applicant: Cedars-Sinai Medical CenterInventors: Pablo Avalos, Doniel Drazin, Clive Svendsen, Michael John Baker, Mark Sasha Drlik
-
Publication number: 20180057788Abstract: The invention relates to culturing brain endothelial cells, and optionally astrocytes and neurons in a fluidic device under conditions whereby the cells mimic the structure and function of the blood brain barrier. Culture of such cells in a microfluidic device, whether alone or in combination with other cells, drives maturation and/or differentiation further than existing systems.Type: ApplicationFiled: November 15, 2016Publication date: March 1, 2018Inventors: Jordan Kerns, Norman Wen, Carol Lucchesi, Christopher Hinojosa, Jacob Fraser, Geraldine Hamilton, Gad Vatine, Sam Sances, Clive Svendsen, Daniel Levner, Dhruv Sareen
-
Publication number: 20170362574Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.Type: ApplicationFiled: June 16, 2016Publication date: December 21, 2017Applicant: Cedars-Sinai Medical CenterInventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
-
Publication number: 20160256672Abstract: Human induced pluripotent stem cell (iPSC) technology combined with a hollow fiber based bioartificial liver (BAL) device can benefit patients with liver failure. Defined iPSC lines can provide unlimited supply of functional hepatocytes by developing iPSC derived hepatocytes (iHeps). Disclosed herein is a protocol for deriving metabolically active hepatocytes from iPSCs. In some embodiments, iHeps were cultured on microcarrier beads in spinner flasks. Subsequently, the iHep-microcarrier complexes were loaded into the extracapillary space of a hollow fiber bioreactor cartridge and cultured using closed circuit continuous flow system. The iHeps secreted human albumin, prothrombin and apolipoprotein B into the hollow fiber intracapillary space media which indicated the maintenance of plasma protein secretory function. In addition, the continuous flow system improved the maturation of iHeps.Type: ApplicationFiled: February 9, 2016Publication date: September 8, 2016Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Vaithilingaraja Arumugaswami, Clive Svendsen